EUVIMEDEUVIMED entdecken
Crossref

ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis

Sichen Di, Ji Liu, Zhuoran Gu, Chengqi Jin, Junfeng Zhang, Keqiang Li, Yongqiang Liu, Haotian Chen, Wei Yang, Wenjin Chen, Wentao Zhang, Shiyu Mao und 4 weitere

International Immunopharmacology · 2026-09 · 185 · 117006

DOI: 10.1016/j.intimp.2026.117006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-09. Verfasst von Sichen Di und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200000, China.; Urologic Cancer Institute, To…. Hauptthemen laut MEDLINE: Sunitinib, Carcinoma, Renal Cell, Drug Resistance, Neoplasm, Kidney Neoplasms. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, Anhui Provincial Department of Education, Tongji University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SunitinibCarcinoma, Renal CellDrug Resistance, NeoplasmKidney NeoplasmsLipid MetabolismArachidonate 5-LipoxygenaseAntineoplastic AgentsHumansAnimalsCell Line, TumorPPAR alphaMiceFemaleGene Expression Regulation, Neoplasticp38 Mitogen-Activated Protein KinasesMaleMice, NudeProtein Kinase Inhibitors

Stichwörter der Autor:innen

ALOX5Fatty acid oxidationLipid metabolic reprogrammingRenal cell carcinomaSunitinib resistance

Substanzen

SunitinibArachidonate 5-LipoxygenaseALOX5 protein, humanAntineoplastic AgentsPPAR alphaPPARA protein, humanp38 Mitogen-Activated Protein KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200000, China.; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai 200000, China.
  • Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200082, China.
  • Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200000, China.; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai 200000, China.. Electroni…
  • Department of Urology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.. Electronic address: 3288993092@qq.com.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • Anhui Provincial Department of Education
  • Tongji University
  • China Postdoctoral Science Foundation
  • National Key Clinical Specialty Discipline Construction Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Di, S., Liu, J., Gu, Z., Jin, C., Zhang, J., Li, K., Liu, Y., Chen, H., Yang, W., Chen, W., Zhang, W., Mao, S., Hao, Y., Zhang, H., Zhu, X., & Yao, X. (2026). ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis. International Immunopharmacology, 185, 117006. https://doi.org/10.1016/j.intimp.2026.117006

Vancouver

Di S, Liu J, Gu Z, Jin C, Zhang J, Li K, et al. ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis. International Immunopharmacology. 2026;185:117006. doi:10.1016/j.intimp.2026.117006

BibTeX
@article{Di2026,
  author = {Di, Sichen and Liu, Ji and Gu, Zhuoran and Jin, Chengqi and Zhang, Junfeng and Li, Keqiang and Liu, Yongqiang and Chen, Haotian and Yang, Wei and Chen, Wenjin and Zhang, Wentao and Mao, Shiyu and Hao, Yajuan and Zhang, Haimin and Zhu, Xiaojun and Yao, Xudong},
  title = {ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {185},
  pages = {117006},
  doi = {10.1016/j.intimp.2026.117006}
}
Kostenlos starten →